Transforming growth factor-β (TGFβ) is a cytokine with autocrine and paracrine action in the testis and potent immunoregulatory and anti-inflammatory activities. In the present study, we examined the concentration of latent (acid-activatable) and free (active) TGFβ in seminal plasma from normal subjects (n ⍧ 23) and infertile (n ⍧ 40) patients, by using a TGFβ specific immunoenzymological assay, and a bioassay (CCL64 cell line growth inhibition) detecting any form of TGFβ. Free TGFβ1 was present in normal subjects at a concentration (1.82 ⍨ 1.06 ng/ml) close to that known to give maximal stimulation in vitro. In pathological groups, the mean concentrations were not significantly different from the normal ones. Latent TGFβ1 was present in normal seminal plasma at a high concentration (92.4 ⍨ 29.2 ng/ml). In subjects with pathologies of both testis and genital apparatus, or with epididymal occlusion, mean latent TGFβ1 concentrations were normal, whereas transferrin concentrations were lower. The concentrations found in the epididymal occlusion group indicate that TGFβ1 is, for a large part, secreted by the genital tract. In the testicular pathology group, TGFβ1 concentrations were 130.7 ⍨ 61.2 ng/ml, a mean not statistically different from normal, although higher. No differences were found between patients with high and normal blood plasma follicle stimulating hormone, and this is consistent with the notion that most TGFβ1 in seminal plasma is not of testicular origin. The TGFβ bioassay ensured that immunologically detected TGFβ was present in a bioactive or bioactivatable form. Furthermore, the values found in normal and pathological seminal plasmas were usually higher than those detected by the immunoassay, suggesting that other forms of TGFβ might be present. Together, the present data show that very large amounts of TGFβ are present in human seminal plasma. The TGFβ ligand assay in the seminal plasma appears to indicate no differences between normal and infertile subjects.
Introduction
Transforming growth factors-β (TGFβ) are members of a large family of peptidic growth factors. The TGFβ functional system is complex as it includes at least three ligands: TGFβ1, TGFβ2, TGFβ3, binding proteins, and two receptors. Secreted TGFβ is non-covalently linked to different proteins, leading to an inactive form from which the ligands need to be released for binding to their cognate receptors. The binding proteins comprise LAP (latency associated protein) and the large latent TGFβ1 complex where LAP binds to an additional protein.
These two forms are produced by many cell types, and both can be activated to release mature TGFβ1. In blood serum, mature TGFβ1 released from these complexes is bound covalently to α2-macroglobulin, and is thus inactivatable. A small part of TGFβ1 is linked by a non-covalent interaction with this protein and is thus activatable. In vitro, TGFβ can be released in an active free form ('activated') from these complexes by a variety of treatments, and usually transient acidification is used. Physiologically, the activation is probably carried out by enzymes. TGFβ have a very large spectrum of biological actions both in vivo and in vitro, influencing cell proliferation, differentiation and functional activity, usually by inhibiting these activities in epithelial cells, and stimulating them in cells of mesenchymal origin. Immunoregulatory, antiinflammatory and healing activities, through the regulation of cellular matrix component formation, are also essential functions of the TGFβ family (reviews: Massagué, 1990; Harpel et al., 1992; Sporn and Roberts, 1992; Matzuk, 1995) .
In-vitro experiments conducted in several different species suggested that TGFβ might be implicated in the local control of testicular development and functions. Indeed, TGFβ as well as their receptors are expressed in the testis both in terms of mRNA and protein. TGFβ have been shown to control the proliferation of mouse primordial germ cells and the functions of Leydig and Sertoli cells by inhibiting gonadotrophin effects, and to control peritubular myoid cells by stimulating extracellular matrix production (reviews: Benahmed, 1996; Gnessi et al., 1997) . TGFβ1 might also inhibit prostate growth both in vivo (Ilio et al., 1995; Nishi et al., 1996) and in vitro (Kim et al., 1996) and its secretion by rat prostatic cells was demonstrated in vitro (Steiner et al., 1994) . Finally, in humans, both free and latent forms of TGFβ1 were found on spermatozoa (Chu et al., 1996) . In addition, TGFβ may exert an immunosuppressive action in the male reproductive tract as in other tissues, but few data are available on this point (Pöllänen et al., 1993) .
Following these different observations, our aim in the present study was to identify and measure TGFβ in seminal plasma TGFβ has been demonstrated to be present in pools of human seminal plasma, by testing for inhibition of CCL64 cell multiplication (Lokeshwar and Block, 1992; Nocera and Chu, 1993) , or by using an immunoassay (Nocera and Chu, 1995) . Another immunoassay study involved three samples of seminal plasma from normal patients (Shrivastava et al., 1996) . These data are based on a limited number of samples, and as far as we know, no data are available on human male reproductive pathology.
In this study, we quantified TGFβ1 in human seminal plasma from 63 subjects by using a specific immunological assay, and checked that the TGFβ were in an active or activatable form, by using a bioassay. We also investigated the relationship between seminal plasma TGFβ and the normal or diseased status of the patients.
Materials and methods

Subjects
A 3-5 day sexual abstinence was required from the subjects before semen collection. After liquefaction and centrifugation, seminal plasma samples were kept at -20°C until assayed.
Men were allocated into groups (Table I) according to clinical and biological data: testicular secretory pathology (15 cases), epididymal occlusion (six cases), and mixed pathology, i.e. patients with both secretory and non-obstructive genital tract pathology (19 cases). In 23 cases, no abnormalities were found; clinical examinations and spermiograms were normal (spermatozoa/ml Ͼ20ϫ10 6 ; motility Ͼ40%; normal forms Ͼ60%), and couple infertility was related to the female partner. This group was considered as a control population, although the fertility of all subjects of this 'control' population could not be demonstrated, since most couples went to the clinician for primary infertility.
Spermiograms were carried out according to World Health Organization (1987) recommendations. As a part of the biological exploration, blood follicle stimulating hormone (FSH) was assayed in all subjects (normal values: 1-7 mU/ml, FSH-Coatria; BioMérieux, Marcy l'Etoile, France).
In most patients, all TGFβ concentrations were measured by using the same seminal plasma sample. Due to small seminal plasma volumes, 11 patients were given only a free TGFβ1 assay.
TGFβ assays
Immunological assay TGFβ1 concentrations were measured in the seminal plasma of each patient by using a specific commercial kit (Quantikine, R & D systems, Abingdon, UK). This assay is based on the quantitative sandwich enzyme immunoassay technique, with soluble TGFβ receptor type II and an enzyme-linked polyclonal TGFβ1-specific antibody. According to the manufacturer, a 0.9% cross-reactivity was observed with TGFβ3, but no cross-reactivity was observed with TGFβ2.
Acidic activation of the samples was performed according to the manufacturer's directions for blood serum: addition of 1 volume of 2.5 N acetic acid/10 mol/l urea, 15 min incubation at room temperature, neutralization by addition of 1 volume 2.7 N NaOH/1 mol/l HEPES. In these samples, 'activatable' TGFβ1 was the sum of free TGFβ1 and TGFβ1 released from latent complexes. These acidified samples were diluted from 1/100 to 1/800 and measured at four different dilutions (chemicals were obtained from Sigma Chemical Co., St. Louis, MO, USA).
For the free active TGFβ1 assay, the acidic activation step was omitted. The samples were diluted at 1/4, 1/8 and 1/16 and measured. In all free and activated samples, a correct parallelism with the standard curve was obtained.
Biological assay
The CCL64 mink lung epithelial cell line assay was used. This test is based on TGFβ-induced inhibition of cell proliferation, as measured by a decrease of the incorporation of [ 3 H]thymidine (Amersham Pharmacia Biotech, Buckingham, UK) into DNA when TGFβ are present. The growth of these cells is inhibited by all forms of TGFβ.
CCL64 cells were cultured in Dulbecco's modified essential medium, supplemented with 10% fetal calf serum (FCS) and penicillin-treptomycin. The cells were trypsinized for the testing, and 3ϫ10 4 cells were seeded per well (1.75 cm 2 ). Standard TGFβ1 and diluted seminal plasma samples were incubated with the cells for 48 h in the same medium but with 3% FCS. [ 3 H]Thymidine (250 nCi) was added for the last 15 h. The medium was then removed, and the cells were washed with PBS, trichloracetic acid, water, and methanol, to eliminate the free [ 3 H]thymidine. The cells were then dissolved in 0.5 mol/l NaOH, and a liquid scintillation counter was used to measure the radioactivity.
Samples of seminal plasma were or were not acidified, as described for the immunoassay, and diluted in culture medium for the assay. With no other treatment, parallelism with the standard curve was obtained only with samples at high dilutions, due to the presence of interfering substances in seminal plasma. For example, this might be likely due to interactions between spermine in seminal plasma and FCS generating toxic free radicals. In an effort to overcome this problem, we treated seminal plasma samples with PEG (polyethylene glycol 6000, 6% final concentration) before dilution in culture medium. This procedure precipitated some proteins. Free and activatable TGFβ1 present in the sample could be quantified in the supernatant fraction after PEG treatment. In treated samples, intra-assay reproducibility varied from 6 to 24% from high to low levels, and the overall interassay reproducibility was 20.2%.
Transferrin determination
Transferrin was also measured in the same samples, as a marker for Sertoli cell activity. Transferrin was radioimmunoassayed by using human holotransferrin (Sigma, L'Isle d'Abeau, France), both as a standard and for iodination, which was performed by the chloramine T method (Greenwood et al., 1963) . Radiolabelled product and free iodide were separated on a column of G 50 Sephadex (Pharmacia, Uppsala, Sweden), eluted with phosphate-buffered saline. A human transferrin antiserum (Sigma, T6265, batch 041H-8814) was used. This antiserum did not recognize lactoferrin, also present in seminal fluid. The radioimmunoassay was performed for 48 h, at 4°C, and free and bound radioactivity were separated using g-globulins and PEG (12.5% final concentration). Each sample was assayed in triplicate, at three different dilutions. Values in parentheses are numbers of samples. Seminal free and activatable TGFβ1 and transferrin concentrations from fertile (Normal) and infertile subjects (cf. Table I ).
Statistical analysis
Results are presented as means Ϯ SD. The Mann-Whitney test was used to determine statistical differences between means, and linear correlation coefficients (r) were used for correlation calculations.
Results
Immunological TGFβ1 and transferrin in human seminal plasma
In normal subjects, activatable TGFβ1 ranged from 43.0 to 143.3 ng/ml (Table II) . Free TGFβ1 varied from Ͻ0.5 to 4.54 ng/ml. When the two assays were performed in the same seminal fluid specimen, the percentage of free to activatable TGFβ1 was 1.98 Ϯ 1.60% (Ͻ0.70 to 6.12%), and no correlation was found between the concentrations of activatable and free TGFβ1 (r ϭ -0.07, not significant).
Transferrin concentrations in this group were 30.7 Ϯ 11.3 µg/ml. No correlation was found between activatable TGFβ1 and transferrin concentrations (r ϭ 0.265, not significant), nor between free TGFβ1 and transferrin concentrations (r ϭ 0.379, not significant).
In pathological groups, although activatable TGFβ1 concentrations tended to be higher in occlusive and mixed pathological groups than in normal subjects, the difference was not statistically significant. In the secretory pathological group, the mean value was 130.7 ng/ml, versus 92.9 ng/ml in fertile subjects, still higher than in the other pathological groups. However, the Mann-Whitney test did not give a significant result. In this group, no difference was found between the subgroup with normal blood FSH (n ϭ 8, TGFβ1 ϭ 130.8 Ϯ 58.0 ng/ml) and the subgroup with elevated blood FSH concentrations (n ϭ 5, TGFβ1 ϭ 130.7 Ϯ 73.1 ng/ml).
Free TGFβ1 concentrations were found to be not statistically different between normal and any pathological group.
Transferrin concentrations were lower in secretory, mixed, and occlusive pathological groups, as expected since it originates mainly from the testis. No correlation was found between transferrin and free or activatable TGFβ1 concentrations.
Biological TGFβ
The samples of acidified seminal plasma inhibited CCL64 cell growth. At high dilutions, a dose-dependent effect was demonstrated. At low dilutions, the effect of TGFβ was counterbalanced probably by some growth-stimulating substances present in the seminal plasma, or a substance inhibiting TGFβ activity. In the non-acidified samples, the inhibitory effect was also demonstrated (Figure 1, top) . These substances were either present in low quantities or active only at high concentrations, since the sample was inactive when diluted. The inhibitory activity was removed after PEG precipitation (Figure 1, bottom) , suggesting that it was protein-based. Moreover, after PEG precipitation, free and activatable TGFβ were quantifiable, the assays yielding data paralleling the standard curve (Figure 1 ).
In addition, free and activatable TGFβ concentrations were higher, as a rule, than the values measured by the immunological assay, both in men with normal spermiograms and in infertile men (Table III) .
Discussion
The aim of the present study was (i) to evaluate seminal TGFβ1 concentrations (immunoassay); (ii) to check the bioactivity of TGFβ as well as to detect other forms of seminal TGFβ (bioassay) and (iii) to determine whether there are differences in TGFβ concentrations in seminal plasma from infertile men, compared to fertile men.
We found high concentrations of both free and activatable TGFβ1 in seminal plasma from fertile and infertile men, as detected by the immunoassay. Parallelism of samples with the standard curve suggests that seminal plasma TGFβ1 and the recombinant TGFβ1 used as a standard in the assay are antigenically similar.
Due to the low percentage of free TGFβ1 present before acidification, values obtained for activatable TGFβ1 may be considered as representative of the latent stock form. In our study, normal activatable TGFβ1 concentrations varied largely, as seminal plasma parameters do. The normal latent TGFβ1 concentrations obtained in the present study (92.4 Ϯ 29.2 ng/ml) are similar to those reported (Shrivastava et al., 1996) (71.0 Ϯ 32.1 ng/ml in three samples of normal seminal plasma) but lower than those obtained by Nocera and Chu (Nocera and Chu, 1995) (238 ng/ml in four pools of seminal plasma from vasectomized subjects). As for free TGFβ1, we As for Top, after seminal plasma partial purification (i.e. PEG purification). In both cases, seminal plasma samples were first diluted in the culture medium according to the data from immunological assays, from 1/50 to 1/ 150 according to the samples. From this point onward, serial 1/2 dilutions were performed, and used in the biological assay. Values are means Ϯ SD. Assays were performed in a pool of seminal plasma, and in individual samples, from normal subjects and from patients with secretory or mixed pathology. Secretory ϭ secretory (testicular) pathology; Mixed ϭ non-obstructive genital tract pathology ϩ testicular pathology.
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found lower values than Shrisvastava et al. (Shrivastava et al., 1996) (9.2 ng/ml). It is of interest to note that both in the present and earlier studies, high concentrations of TGFβ1 were found in seminal plasma. The presence of such high concentrations of TGFβ1, 100-fold higher than is required to activate the receptors in vitro (which is 1-2 ng/ml; Benahmed et al., 1989; Esposito et al., 1991; Morera et al., 1992; Besset et al., 1994; Ilio et al., 1995; Kim et al., 1996) is intriguing. Even free (active) TGFβ1 is present at concentrations that allow full activity of the peptide. The occurrence of such high concentrations of free and activatable TGFβ1 raises the question as to whether the conversion of inactive to active peptide is a key regulatory step in seminal plasma, as has been suggested for different tissues (Harpel et al., 1992) . The biological estimate of TGFβ was less accurate than the immunological determination. Nevertheless, the CCL64 cell assay has the advantage of detecting all forms of the ligand, thereby providing an estimate of its total activity in seminal plasma. The results obtained were the sum of TGFβ1, TGFβ2 and other forms, if present. This also allowed us to ascertain that the TGFβ immunologically detected was not an inactive peptide in seminal plasma.
When secreted, latent TGFβ is non-covalently linked to different proteins. Nocera and Chu (Nocera and Chu, 1993) , in identifying TGFβ as an immunosuppressive molecule in seminal plasma by gel filtration, found this activity in fractions of 100 to Ͼ440 kDa, i.e. complexed, since free mature TGFβ has a mol. wt of 25 kDa. It is not known if complex(es) present in seminal fluid are identical or different from those found in blood. α2-Macroglobulin is a potential TGFβ-binding protein, since it is present in seminal plasma at~10 µg/ml (Glander et al., 1996) .
TGFβ concentrations in seminal plasma might be higher that those measured by the immunological assay, since the biological assay consistently gave higher values. Therefore other forms of TGFβ, i.e. TGFβ2, TGFβ1-2 and TGFβ3, may well be present in seminal plasma, and indeed TGFβ2 was found in human seminal plasma (Nocera and Chu, 1995; Shrivastava et al., 1996) . The functions of these other peptides, as demonstrated in vitro, are not very different from those of TGFβ1 (reviews: Massagué, 1990; Sporn and Roberts, 1992; Matzuk, 1995) , but mice with non-functional genes for TGFβ1 or TGFβ2 exhibit different phenotypes (Sanfort et al., 1997) .
The absence of correlation between TGFβ1 and transferrin concentrations, and the normal values obtained in cases of epididymal occlusion, where testicular secretions cannot contribute to seminal plasma formation, suggest that the testis and the epididymis contribute only partly to the final TGFβ1 concentration in seminal plasma. It will be of interest to determine the extratesticular origin of the TGFβ1 present in the seminal plasma. Furthermore, no differences were found in the secretory group between patients with high or normal blood plasma FSH, suggesting again that most seminal plasma TGFβ1 was probably not under testicular hormonal control.
A role of this growth factor in regulating growth and functions of testicular somatic cells has been demonstrated in vitro (reviews: Benahmed, 1996; Gnessi et al., 1997 seminal TGFβ1 concentrations and normal versus pathological testicular status, possibly because other regions of the reproductive tract secrete the ligand. Moreover, the TGFβ ligands we measured here are only a small part of the TGFβ system, which includes, in addition to the ligand, the binding protein(s), the membrane (and probably the soluble) receptors. Therefore, a possible difference between normal and pathological subjects might be found in the levels of these parameters. This observation suggests that it would be of interest to analyse these parameters in seminal plasma of infertile men. Finally, although we observed moderately elevated or decreased activatable TGFβ1 concentrations in a few patients, we do not know at the present time whether these observations are relevant to their infertility. A higher number of patients would be necessary to draw a firm conclusion on that issue.
As we mentioned, normal free TGFβ1 concentrations (Ͻ0.5 to 4.5 ng/ml) were of the same order of magnitude or higher than the concentrations giving maximal effect in vitro. This suggests a local action, possibly repair after local infection and inflammation (Noble et al., 1992 ). An immunosuppressive activity was demonstated in seminal plasma (James and Hargreave, 1984) , and attributed to prostaglandins (Quaile et al., 1989) and to other local factors (Imade et al., 1997) . The TGFβ may also contribute to this activity (Nocera and Chu, 1993; Pöllänen et al., 1993) .
As free and latent TGFβ1 are found on ejaculated spermatozoa (Chu et al., 1996) one may postulate that spermatozoa are coated with locally secreted TGFβ both produced during the spermatogenesis (Caussanel et al., 1997) and/or present in genital tract secretions. TGFβ1 may play a critical role in preventing an immune reaction to spermatozoa in the female reproductive tract (Nocera and Chu, 1993; Chu et al., 1996) . Also, it is possible that it may act on the spermatozoa itself as we have recently observed the presence of immunoreactive TGFβ receptors on specific domains of the male gamete (V.Caussanel, S.Hamamah, A.Hazout, B.Loras, M.Benahmed, unpublished results).
In conclusion, the present data suggest that TGFβ quantification in seminal plasma of infertile patients could be informative probably on the local gonadol immunological status of the patient or on the functional status of the accessory glands, which are responsible for most of the secretion of TGFβ. Based on the published observations obtained from in-vitro studies, and more importantly in the transgenic models which indicate that TGFβ and related peptides may play a key role in spermatogenesis, the analysis of testicular TGFβ expression remains of major interest in oligozoospermic and azoospermic patients. To evaluate the potential critical role of TGFβ in such cases, analysis of the signalling molecules in the testicular (tissues) biopsies is a more suitable approach.
